



## NEWS RELEASE

For Immediate Release: Tuesday, October 18, 2005

Contact: Howard Root, CEO  
James Hennen, CFO  
Vascular Solutions, Inc.  
(763) 656-4300

### CORRECTED Press Release

## VASCULAR SOLUTIONS ANNOUNCES PRESENTATION OF FINAL RESULTS OF “POCKET PROTECTOR” CLINICAL STUDY OF THE D-STAT FLOWABLE

*Presentation of clinical data at the Transcatheter Cardiovascular Therapeutics Meeting*

MINNEAPOLIS, Minnesota -- Vascular Solutions, Inc. (Nasdaq:VASC) today announced a correction of its press release issued earlier today to reflect the final results of the Pocket Protector clinical study.

Vascular Solutions, Inc. (Nasdaq: VASC) announced that the final results of the Pocket Protector clinical study were presented today by Dr. Fawwaz Shoukfeh at the Transcatheter Cardiovascular Therapeutics meeting in Washington D.C.

The Pocket Protector clinical study was a prospective, randomized, multi-center clinical study to assess the safety and effectiveness of the D-Stat® Flowable hemostat in the prepectoral pocket during the implantation of a pulse generator (pacemaker or ICD) in an anti-coagulated population. Patients were randomized to a control group (standard of care using compression, electrocautery or untreated cotton pledgets) and investigation group (D-Stat Flowable hemostat as an adjunct to standard of care) on a 1:1 ratio. The primary endpoints of the Pocket Protector study were a comparison of clinically relevant pocket hematoma formation (effectiveness - superiority) and the rate of major adverse events (safety – non-inferiority). Secondary endpoints included minor complications, duration of procedure, duration of hospitalization and patient satisfaction. Adverse events and hematomas were adjudicated by an independent Clinical Events Committee that was blinded as to treatment mode, and the study was overseen by an independent Data Safety Monitoring Board. The study was performed at 11 U.S. clinical sites with a total of 269 patients enrolled.

Study treatment groups were homogenous for cardiac risk factors, conduction disorders, body mass index, labs, vitals, ethnicity and underlying diagnosis. Primary and secondary endpoints by treatment group were as follows:

	Investigation (n=136)	Control (n=133)	p-Value
Rate of clinically relevant hematomas	11.8%	22.6%	p=0.0231
Device or procedure related rate of major adverse events	8.8%	7.5%	P=0.0083
Patient satisfaction at 8-weeks follow up	96.6%	92.7%	n/a
Minor complication rates	6.6%	7.5%	p=.816

Dr. Shoukfeh commented: "The 48% reduction in hematoma formation observed in the investigation group compared to the control group, and the low overall device or procedure-related major event rates, demonstrate this adjunct device provides a safe and effective means to impact anti-coagulated patient outcomes for this procedure."

The D-Stat Flowable hemostat is a thick, yet flowable, suspension of collagen, thrombin and diluent approved for the local management of active bleeding. The D-Stat Flowable has not been approved by the U.S. FDA for the use described in the Pocket Protector study.

### **About Vascular Solutions**

Vascular Solutions, Inc. is a medical device company that focuses on developing unique solutions for unmet clinical opportunities within Interventional radiology and Interventional cardiology. New products introduced since the second half of 2003 include the Vari-Lase® endovenous laser product line for the treatment of varicose veins, the D-Stat Dry™ hemostatic bandage for the rapid control of topical bleeding, the Pronto™ extraction catheter for the mechanical extraction of soft thrombus and the Langston™ dual lumen catheter for the measurement of aortic stenosis. The Company's other major products include the Duett™ sealing device to rapidly seal the puncture site following catheterization procedures and the Acolysis® intravascular therapeutic ultrasound product which is sold in international markets for the treatment of peripheral occlusive arterial disease.

The information in this press release contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements. Important factors that may cause such differences include those discussed in our Annual Report on Form 10-K for the year ended December 31, 2004 and other recent filings with the Securities and Exchange Commission. The risks and uncertainties include, without limitation, risks associated with the need for adoption of our new products, limited working capital, lack of profitability, exposure to intellectual property claims, dependence on key vendors, exposure to possible product liability claims, the development of new products by others, doing business in international markets, limited manufacturing experience, the availability of third party reimbursement, and actions by the FDA.

For further information, connect to [www.vascularsolutions.com](http://www.vascularsolutions.com).

###